Drug Trial Radar · NCT07884734
A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jun 8, 2026
Primary completion
Oct 31, 2026
Study completion Oct 31, 2026
Sponsor
- Lead sponsor
- GRIN Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, 2-part study in healthy adult participants to evaluate the pharmacokinetics and safety of radiprodil when coadministered with either the CYP3A4 inducer carbamazepine or the CYP3A4 inhibitor itraconazole. Up to 36 participants will be enrolled, with approximately 18 participants in Part A and 18 participants in Part B.
Conditions
- Healthy Adult Participants
Interventions
RadiprodilDrug
Radiprodil administered orally as a single dose of 30 mg in Part A or 15 mg in Part B under fed conditions.
CarbamazepineDrug
Carbamazepine administered orally twice daily at doses of 100 mg, 200 mg, and 300 mg in Part A to evaluate the effect of CYP3A4 induction on the pharmacokinetics of radiprodil.
Itraconazole (200 mg)Drug
Itraconazole administered orally at 200 mg once daily in Part B to evaluate the effect of CYP3A4 inhibition on the pharmacokinetics of radiprodil.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUClast of Radiprodil - Part ATime frame: Part A: Day 1 through Day 19
- AUCinf of Radiprodil - Part ATime frame: Part A: Day 1 through Day 19
- Cmax of Radiprodil - Part ATime frame: Part A: Day 1 through Day 19
- AUClast of Radiprodil - Part BTime frame: Part B: Day 1 through Day 12
- AUCinf of Radiprodil - Part BTime frame: Part B: Day 1 through Day 12
- Cmax of Radiprodil - Part BTime frame: Part B: Day 1 through Day 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
California Clinical Trials Medical Group (CCTMG)
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.